CareDx
CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic solutions for transplant patients worldwide. The last earnings update was 48 days ago. More info.
Add to Portfolio Compare Print
CDNA Share Price and Events
7 Day Returns
1 Year Returns
CDNA Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| CareDx (CDNA) | -11.3% | 8.2% | 1.9% | 185.3% | 634.5% | - |
| US Biotechs | 5% | 4.5% | 1.1% | -3.6% | 23.6% | 11.7% |
| US Market | 2% | 4.1% | 4.2% | 4.3% | 43.9% | 40.8% |
1 Year Return vs Industry and Market
- CDNA outperformed the Biotechs industry which returned -3.6% over the past year.
- CDNA outperformed the Market in United States of America which returned 4.3% over the past year.
CDNA Value
Is CareDx undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
CareDx
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for CareDx.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 5 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 10% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 6% |
| Biotechs Unlevered Beta | Simply Wall St/ S&P Global | 1.32 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.325 (1 + (1- 21%) (0.32%)) |
1.22 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
1.22 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.22 * 5.96%) |
10% |
Discounted Cash Flow Calculation for NasdaqGM:CDNA using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for CareDx is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 10%) |
|
|---|---|---|---|
| 2019 | 1.30 | Analyst x1 | 1.18 |
| 2020 | 26.40 | Analyst x1 | 21.82 |
| 2021 | 81.90 | Analyst x1 | 61.53 |
| 2022 | 121.80 | Analyst x1 | 83.19 |
| 2023 | 156.22 | Est @ 28.26% | 97.00 |
| 2024 | 188.40 | Est @ 20.6% | 106.35 |
| 2025 | 217.12 | Est @ 15.24% | 111.41 |
| 2026 | 242.05 | Est @ 11.49% | 112.92 |
| 2027 | 263.50 | Est @ 8.86% | 111.75 |
| 2028 | 282.00 | Est @ 7.02% | 108.72 |
| Present value of next 10 years cash flows | $815.87 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $282.00 × (1 + 2.73%) ÷ (10% – 2.73%) |
$3,984.70 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $3,984.70 ÷ (1 + 10%)10 |
$1,536.24 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $815.87 + $1,536.24 |
$2,352.10 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $2,352.10 / 42.12 |
$55.84 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $55.84 |
| Current discount | Discount to share price of
$34.23
= -1 x ($34.23 - $55.84) / $55.84 |
38.7% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- CareDx's share price is below the future cash flow value, and at a moderate discount (> 20%).
- CareDx's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for CareDx's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
CareDx's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in USD | $-1.17 |
| NasdaqGM:CDNA Share Price ** | NasdaqGM (2019-06-24) in USD | $34.23 |
| United States of America Biotechs Industry PE Ratio | Median Figure of 35 Publicly-Listed Biotechs Companies | 19.23x |
| United States of America Market PE Ratio | Median Figure of 3,095 Publicly-Listed Companies | 17.88x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of CareDx.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqGM:CDNA Share Price ÷ EPS (both in USD) = 34.23 ÷ -1.17 |
-29.18x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- CareDx is loss making, we can't compare its value to the US Biotechs industry average.
- CareDx is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
CareDx's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -29.18x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts |
85.2%per year |
| United States of America Biotechs Industry PEG Ratio | Median Figure of 26 Publicly-Listed Biotechs Companies | 1.04x |
| United States of America Market PEG Ratio | Median Figure of 2,134 Publicly-Listed Companies | 1.54x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for CareDx, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
CareDx's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in USD | $2.28 |
| NasdaqGM:CDNA Share Price * | NasdaqGM (2019-06-24) in USD | $34.23 |
| United States of America Biotechs Industry PB Ratio | Median Figure of 431 Publicly-Listed Biotechs Companies | 3.01x |
| United States of America Market PB Ratio | Median Figure of 5,255 Publicly-Listed Companies | 1.8x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqGM:CDNA Share Price ÷ Book Value per Share (both in USD) = 34.23 ÷ 2.28 |
15x |
* Primary Listing of CareDx.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- CareDx is overvalued based on assets compared to the US Biotechs industry average.
Value checks
We assess CareDx's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) CareDx has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
CDNA Future Performance
How is CareDx expected to perform in the next 1 to 3 years based on estimates from 5 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- CareDx's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- CareDx's earnings growth is expected to exceed the United States of America market average.
- CareDx's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqGM:CDNA Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts | 85.2% |
| NasdaqGM:CDNA Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts | 40.7% |
| United States of America Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 22.9% |
| United States of America Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 18.1% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 14% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.4% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 5 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2022-12-31 | 390 | 125 | 144 | 2 |
| 2021-12-31 | 262 | 85 | 66 | 2 |
| 2020-12-31 | 164 | 29 | 4 | 5 |
| 2019-12-31 | 115 | 4 | -23 | 5 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | 88 | -5 | -45 |
| 2018-12-31 | 77 | -4 | -47 |
| 2018-09-30 | 66 | -8 | -75 |
| 2018-06-30 | 57 | -11 | -69 |
| 2018-03-31 | 51 | -12 | -59 |
| 2017-12-31 | 48 | -14 | -55 |
| 2017-09-30 | 47 | -15 | -39 |
| 2017-06-30 | 47 | -14 | -29 |
| 2017-03-31 | 46 | -17 | -35 |
| 2016-12-31 | 41 | -17 | -39 |
| 2016-09-30 | 36 | -17 | -29 |
| 2016-06-30 | 31 | -19 | -28 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 5 Analyst Estimates (S&P Global) | See Below |
All data from CareDx Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2022-12-31 | 3.36 | 3.36 | 3.36 | 1.00 |
| 2021-12-31 | 1.56 | 1.56 | 1.56 | 1.00 |
| 2020-12-31 | 0.09 | 0.30 | -0.09 | 4.00 |
| 2019-12-31 | -0.54 | -0.46 | -0.60 | 4.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2019-03-31 | -1.17 |
| 2018-12-31 | -1.31 |
| 2018-09-30 | -2.29 |
| 2018-06-30 | -2.38 |
| 2018-03-31 | -2.32 |
| 2017-12-31 | -2.38 |
| 2017-09-30 | -1.81 |
| 2017-06-30 | -1.38 |
| 2017-03-31 | -1.87 |
| 2016-12-31 | -2.39 |
| 2016-09-30 | -2.03 |
| 2016-06-30 | -2.31 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess CareDx's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
CareDx has a total score of 6/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
CDNA Past Performance
How has CareDx performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- CareDx does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare CareDx's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare CareDx's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from CareDx Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | 88.50 | -45.32 | 50.27 | |
| 2018-12-31 | 76.57 | -46.76 | 43.63 | |
| 2018-09-30 | 65.56 | -74.67 | 39.30 | |
| 2018-06-30 | 56.57 | -68.97 | 35.44 | |
| 2018-03-31 | 50.79 | -58.88 | 31.39 | |
| 2017-12-31 | 48.32 | -55.47 | 31.72 | |
| 2017-09-30 | 46.68 | -39.28 | 31.52 | |
| 2017-06-30 | 46.96 | -28.78 | 32.85 | |
| 2017-03-31 | 45.65 | -35.28 | 34.20 | |
| 2016-12-31 | 40.63 | -39.47 | 31.89 | |
| 2016-09-30 | 36.42 | -28.75 | 29.08 | |
| 2016-06-30 | 31.10 | -28.47 | 25.88 | |
| 2016-03-31 | 27.49 | -21.19 | 21.98 | |
| 2015-12-31 | 28.14 | -13.71 | 20.60 | |
| 2015-09-30 | 29.45 | -8.95 | 18.99 | |
| 2015-06-30 | 28.95 | -4.25 | 17.30 | |
| 2015-03-31 | 28.60 | -0.19 | 16.37 | |
| 2014-12-31 | 27.31 | 0.78 | 14.91 | |
| 2014-09-30 | 25.21 | 0.22 | 13.28 | |
| 2014-06-30 | 24.36 | -1.82 | 12.52 | |
| 2014-03-31 | 23.04 | -3.50 | 11.34 | |
| 2013-12-31 | 22.10 | -3.54 | 10.70 | |
| 2012-12-31 | 20.45 | -5.06 | 10.11 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if CareDx has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if CareDx has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if CareDx improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess CareDx's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
CareDx has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
CDNA Health
How is CareDx's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up CareDx's finances.
The net worth of a company is the difference between its assets and liabilities.
- CareDx is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- CareDx's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 178.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from CareDx Company Filings, last reported 2 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | 95.62 | 0.00 | 57.43 |
| 2018-12-31 | 95.93 | 0.00 | 64.62 |
| 2018-09-30 | 44.39 | 13.38 | 26.20 |
| 2018-06-30 | 28.95 | 13.34 | 16.25 |
| 2018-03-31 | 33.39 | 10.19 | 18.70 |
| 2017-12-31 | -5.95 | 34.06 | 16.90 |
| 2017-09-30 | -0.18 | 36.17 | 5.98 |
| 2017-06-30 | 11.99 | 33.89 | 9.10 |
| 2017-03-31 | 14.86 | 32.39 | 12.19 |
| 2016-12-31 | 19.76 | 23.94 | 17.26 |
| 2016-09-30 | 36.78 | 26.40 | 22.27 |
| 2016-06-30 | 32.51 | 28.21 | 17.14 |
| 2016-03-31 | 20.46 | 15.79 | 23.75 |
| 2015-12-31 | 29.49 | 15.75 | 29.89 |
| 2015-09-30 | 33.90 | 15.72 | 33.95 |
| 2015-06-30 | 36.77 | 15.77 | 36.89 |
| 2015-03-31 | 39.47 | 15.67 | 38.99 |
| 2014-12-31 | 41.30 | 11.41 | 36.43 |
| 2014-09-30 | 41.04 | 12.73 | 39.05 |
| 2014-06-30 | -0.66 | 18.77 | 7.87 |
| 2014-03-31 | -15.67 | 15.08 | 4.84 |
| 2013-12-31 | -14.95 | 15.38 | 5.13 |
| 2012-12-31 | -12.00 | 14.87 | 5.86 |
- CareDx's level of debt (0.5%) compared to net worth is satisfactory (less than 40%).
- CareDx had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- CareDx has sufficient cash runway for more than 3 years based on current free cash flow.
- CareDx has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -12.5% each year.
Financial health checks
We assess CareDx's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) CareDx has a total score of 6/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
CDNA Dividends
What is CareDx's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
CareDx
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate CareDx's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate CareDx's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 5 Analyst Estimates (S&P Global) | See Below |
| Global Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 19 Stocks | 2.3% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2012 Stocks | 2.4% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2022-12-31 | ||
| 2021-12-31 | ||
| 2020-12-31 | ||
| 2019-12-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as CareDx has not reported any payouts.
- Unable to verify if CareDx's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess CareDx's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can CareDx afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) CareDx has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
CDNA Management
CEO
| COMPENSATION | $5,231,391 |
| AGE | 51 |
| TENURE AS CEO | 6.7 years |
CEO Bio
Dr. Peter Maag, PhD has been the Chief Executive Officer of CareDx, Inc. since October 2012 and was its President since October 2012 until November 26, 2018. Dr. Maag accelerated growth in XDx's blood screening business. Dr. Maag held numerous positions with increasing responsibility at Novartis International AG, a global healthcare company from September 2001 to April 2012. He served as the Global Head of Diagnostics - Novartis Vaccines and Diagnos for Novartis AG from 2009 to 2012. He served as Country President for Novartis Pharma AG in Germany from 2006 to 2008. He served as the Head of Novartis Germany Subsidiary of Novartis Ag since July 1, 2006. He served as Head of Strategy for the pharmaceutical division of Novartis A.G. from 2001 to 2002. He worked at McKinsey & Company in New Jersey and Germany, focusing on pharmaceuticals and globalization strategies from 1995 to 2001. He developed the group's infectious diseases business field in 2003 and took over responsibility for Novartis' operations in South Korea in 2004. He serves as a Director of MolecularMD Corp. He has been a Director of CareDx, Inc since November 2012. He serves as a Member of Advisory Board at PHOENIX Pharmahandel GmbH & Co KG. He studied pharmaceutical sciences in Heidelberg and London and received his Ph.D. degree from the University of Berlin, Germany.
CEO Compensation
- Peter's compensation has increased whilst company is loss making.
- Peter's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the CareDx management team in years:
- The tenure for the CareDx management team is about average.
Management Team
Peter Maag
CEO & Director
$5M
51
6.7 yrs
Reg Seeto
President & Chief Business Officer
$4M
46
0.6 yrs
Michael Bell
Chief Financial Officer
$2M
49
2.2 yrs
James Yee
Chief Medical Officer
$697K
69
12.8 yrs
Anders Karlsson
Chief International Business Officer
54
3.2 yrs
Sasha King
Chief Commercial Officer
32
2 yrs
Charles Constanti
Executive Officer
54
2.2 yrs
Board of Directors Tenure
Average tenure and age of the CareDx board of directors in years:
- The tenure for the CareDx board of directors is about average.
Board of Directors
Michael Goldberg
Chairman of the Board
$329K
60
7.6 yrs
Peter Maag
CEO & Director
$5M
51
6.6 yrs
Fred Cohen
Independent Director
$243K
62
16.4 yrs
Ralph Snyderman
Independent Director
$255K
78
14.1 yrs
George Bickerstaff
Independent Director
$257K
62
5.2 yrs
Jeff Bluestone
Member of Advisory Board
65
Mary Crow
Member of Advisory Board
Rob Tibshirani
Member of Advisory Board
Bill Hagstrom
Director
$245K
61
4.3 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 05. Jun 19 | Sell | William Hagstrom | Individual | 04. Jun 19 | 04. Jun 19 | -15,000 | $32.35 | $-485,250 | ||
| 15. Mar 19 | Sell | Michael Goldberg | Individual | 14. Mar 19 | 14. Mar 19 | -50,000 | $37.36 | $-1,867,825 | ||
| 12. Mar 19 | Sell | Peter Maag | Individual | 11. Mar 19 | 11. Mar 19 | -50,000 | $34.23 | $-1,711,280 | ||
| 01. Dec 18 | Sell | Peter Maag | Individual | 28. Nov 18 | 29. Nov 18 | -100,000 | $28.59 | $-2,852,512 | ||
| 02. Nov 18 | Sell | Gagnon Advisors, LLC | Company | 31. Oct 18 | 31. Oct 18 | -98,150 | $27.05 | $-2,654,712 | ||
| 02. Nov 18 | Sell | Gagnon Securities LLC | Company | 31. Oct 18 | 31. Oct 18 | -10,449 | $27.05 | $-282,619 | ||
| 01. Aug 18 | Sell | Sasha King | Individual | 01. Aug 18 | 01. Aug 18 | -3,000 | $14.03 | $-42,102 | ||
| 12. Jul 18 | Sell | Mitchell Nelles | Individual | 02. Jul 18 | 02. Jul 18 | -7,750 | $12.48 | $-96,738 | ||
Management checks
We assess CareDx's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) CareDx has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
CDNA News
Simply Wall St News
Is CareDx, Inc (NASDAQ:CDNA) Trading At A 37% Discount?
In this article we are going to estimate the intrinsic value of CareDx, Inc (NASDAQ:CDNA) by estimating the company's future cash flows and discounting them to their present value. … Generally we assume that a dollar today is more valuable than a dollar in the future, and so the sum of these future cash flows is then discounted to today's value: 10-year free cash flow (FCF) forecast 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 Levered FCF ($, Millions) $1.30 $26.40 $81.90 $121.80 $156.22 $188.40 $217.12 $242.05 $263.50 $282.00 Growth Rate Estimate Source Analyst x1 Analyst x1 Analyst x1 Analyst x1 Est @ 28.26% Est @ 20.6% Est @ 15.24% Est @ 11.49% Est @ 8.86% Est @ 7.02% Present Value ($, Millions) Discounted @ 10.24% $1.18 $21.72 $61.13 $82.46 $95.94 $104.96 $109.71 $110.95 $109.56 $106.36 Present Value of 10-year Cash Flow (PVCF)= $803.98m "Est" = FCF growth rate estimated by Simply Wall St After calculating the present value of future cash flows in the intial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. … Terminal Value (TV) = FCF2029 × (1 + g) ÷ (r – g) = US$282m × (1 + 2.7%) ÷ (10.2% – 2.7%) = US$3.9b Present Value of Terminal Value (PVTV) = TV / (1 + r)10 = $US$3.9b ÷ ( 1 + 10.2%)10 = $1.45b The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is $2.26b.
Simply Wall St - – Full articleShould You Be Concerned About CareDx, Inc's (NASDAQ:CDNA) Historical Volatility?
Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … Small companies often have a high beta value because the stock price can move on relatively low capital flows. … So it's interesting to note that this stock historically has a beta value quite close to one.
Simply Wall St - – Full articleWhat Did CareDx, Inc's (NASDAQ:CDNA) CEO Take Home Last Year?
This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … Then we'll look at a snap shot of the business growth. … How Does Peter Maag's Compensation Compare With Similar Sized Companies?
Simply Wall St - – Full articleCareDx, Inc (NASDAQ:CDNA) Is Expected To Breakeven
CareDx, Inc's (NASDAQ:CDNA):. … CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic solutions for transplant patients worldwide. … In this article, I will touch on the expectations for CDNA’s growth and when analysts expect the company to become profitable
Simply Wall St - – Full articleDid CareDx, Inc (NASDAQ:CDNA) Insiders Sell Shares?
So we'll take a look at whether insiders have been buying or selling shares in CareDx, Inc (NASDAQ:CDNA). … In the last twelve months, the biggest single sale by an insider was when CEO & Director Peter Maag sold US$2.9m worth of shares at a price of US$28.59 per share. … That means that even when the share price was below the current price of US$36.90, an insider wanted to cash in some shares.
Simply Wall St - – Full articleWhy We Think CareDx, Inc (NASDAQ:CDNA) Could Be Worth Looking At
CareDx, Inc (NASDAQ:CDNA) is a stock with outstanding fundamental characteristics. … When we build an investment case, we need to look at the stock with a holistic perspective. … In the case of CDNA, it
Simply Wall St - – Full articleWhat Did CareDx, Inc's (NASDAQ:CDNA) CEO Take Home Last Year?
This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … Participate in a short research study and receive a 6-month subscription to the award winning Simply Wall St research tool (valued at $60) … How Does Peter Maag's Compensation Compare With Similar Sized Companies?
Simply Wall St - – Full articleLoss-Making CareDx, Inc (NASDAQ:CDNA) Expected To Breakeven
CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. … The US$1.0b market-cap posted a loss in its most recent financial year of -US$55.5m and a latest trailing-twelve-month loss of -US$74.7m leading to an even wider gap between loss and breakeven. … View our latest analysis for CareDx
Simply Wall St - – Full articleShould You Be Worried About Insider Transactions At CareDx, Inc (NASDAQ:CDNA)?
So shareholders might well want to know whether insiders have been buying or selling shares in CareDx, Inc (NASDAQ:CDNA). … In the last twelve months, the biggest single sale by an insider was when CEO & Director Peter Maag sold US$2.9m worth of shares at a price of US$28.59 per share. … So we know that an insider sold shares at around the present share price of US$24.38.
Simply Wall St - – Full articleDoes CareDx Inc (NASDAQ:CDNA) Have A Particularly Volatile Share Price?
If you're interested in CareDx Inc (NASDAQ:CDNA), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.
Simply Wall St - – Full articleCDNA Company Info
Description
CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic solutions for transplant patients worldwide. The company develops and provides a diagnostic surveillance testing solution for heart and kidney transplant recipients. It offers AlloMap, a heart transplant molecular test; and AlloSure, a donor-derived cell-free DNA test initially used for kidney transplant patients. The company also develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and organs. It sells Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence-specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables speed and precision in HLA typing at a low to intermediate resolution for samples that require a fast turn-around-time and uses real-time polymerase chain reaction methodology; and TruSight HLA, a high resolution solution that uses next generation sequencing methodology. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina for the development, commercialization, and distribution of next generation sequencing product line for use in transplantation diagnostic testing. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.
Details
| Name: | CareDx, Inc |
| CDNA | |
| Exchange: | NasdaqGM |
| Founded: | 1998 |
| $1,441,764,621 | |
| 42,119,913 | |
| Website: | http://www.caredxinc.com |
| Address: |
CareDx, Inc 3260 Bayshore Boulevard, Brisbane, California, 94005, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqGM | CDNA | Common Stock | Nasdaq Global Market | US | USD | 18. Jul 2014 | |
| DB | 1K9 | Common Stock | Deutsche Boerse AG | DE | EUR | 18. Jul 2014 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/06/25 00:13 |
| End of day share price update: | 2019/06/24 00:00 |
| Last estimates confirmation: | 2019/06/24 |
| Last earnings filing: | 2019/05/08 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
